(MENAFN) Mylan N.V., the global generic and specialty Pharmaceuticals Company registered in the Netherlands, offered to buy Meda AB, the Sweden-based international specialty pharmaceutical company for USD9.9bn.
Mylan pursued this purchase basically for the sake of broadening and deepening its global reach, not to mention an estimated pre-tax USD350 million a year in operational savings, which is considered to be a legit motive.
Through a recent couple of acquisitions, Mylan has grown from the third-largest generic and Pharmaceuticals Company in the United States to the second-largest generic and specialty Pharmaceuticals Company in the world.
"Meda brings us greater scale, breadth and diversity across products, geographies and sales channels, and together we will have an even stronger global commercial infrastructure," stated Mylan's Chief executive officer.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.